论文部分内容阅读
高剂量甲氨蝶呤(HDMTX)是治疗淋巴瘤和骨肉瘤的基石药物。在临床应用中,甲氨蝶呤的个体差异性较大,产生的严重毒性无法预估,因此需要个体化的用药方案。
High dose methotrexate (HDMTX) is the cornerstone for the treatment of lymphoma and osteosarcoma. In clinical applications, methotrexate individual differences greater serious toxicity can not be predicted, so the need for individualized drug program.